Navigation Links
Alexza to Announce 2007 Financial Results and Update Its Clinical Pipeline on Monday, March 17, 2008
Date:3/12/2008

tions that, if they prove incorrect, would cause its results to differ materially from those expressed or implied by such forward-looking statements. These and other risks concerning Alexza's business are described in additional detail in the Company's Annual Report on Form 10-K for the year ended December 31, 2007, and the Company's other Periodic and Current Reports filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and we undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Michael J. Simms Joins Alexza Pharmaceuticals as Senior Vice President, Operations and Manufacturing
2. Alexza Initiates First Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)
3. Alexzas Corporate Presentation to be Webcast at the 10th Annual BIO CEO & Investor Conference
4. Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference to Webcast Alexzas Corporate Presentation
5. Alexza Announces Partnership With Endo for AZ-003 (Staccato(R) fentanyl) in North America
6. Alexza Elects Dr. Hal V. Barron to Its Board of Directors
7. 19th Annual Piper Jaffray Health Care Conference to Webcast Alexzas Corporate Presentation
8. The 4th Annual BIO Investor Forum to Webcast Alexzas Corporate Presentation
9. Nile Therapeutics to Announce 2007 Fourth Quarter and Full Year Financial Results on Thursday, March 13, 2008
10. DMetrix and the Armed Forces Radiobiology Research Institute Announce Cooperative Research and Development Agreement
11. Raven Announces RAV12 Phase 1/2a Study Results To Be Presented at ASCO
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... 20, 2014 The report, ... Oligos, Enzymes, Cloning kits), Technology (Bioinformatics, Nanotechnology, ... Pharmaceuticals, Biomaterials, Bioremediation) - Global Forecast to ... drivers, threats, opportunities, and challenges. , Browse ... spread through 185 pages and in-depth TOC ...
(Date:11/21/2014)... Why did Stephen Hawking become so famous? ... recognizable? Why have they become icons to rival film ... Ratcliffe seeks out the answers to those questions, and ... with science. In " Stephen Hawking Smoked My Socks ... Ratcliffe puts it plainly: , “It is profoundly ...
(Date:11/21/2014)... Polaris Group announced today that the ... 1 trial of ADI-PEG 20 in combination with ... pleural mesothelioma (MPM) and non-squamous non-small cell lung ... ADI-PEG 20, both as monotherapy and in combination ... other indications, including breast cancer, melanomas, ovarian cancer, ...
(Date:11/21/2014)... - BIOREM Inc. (TSXV: BRM) ("Biorem" or "the Company") today announced results ... 2014.  Biorem,s complete 2014 third quarter financial statements and MD&A have ... ended September 30, , Nine-months ended September ... 2014 , 2013 , 2014 , ... , 6,715 , 14,476 Gross profit , ...
Breaking Biology Technology:Synthetic Biology Market Expected to Reach $5,630.4 Million in 2018 - New Report by MarketsandMarkets 2Synthetic Biology Market Expected to Reach $5,630.4 Million in 2018 - New Report by MarketsandMarkets 3Synthetic Biology Market Expected to Reach $5,630.4 Million in 2018 - New Report by MarketsandMarkets 4“Stephen Hawking Smoked My Socks” Sparks Controversy in Science World 2“Stephen Hawking Smoked My Socks” Sparks Controversy in Science World 3“Stephen Hawking Smoked My Socks” Sparks Controversy in Science World 4Polaris Group Announces Treatment of First Patient in Phase 1 Study of ADI-PEG 20 plus Pemetrexed and Cisplatin in Malignant Pleural Mesothelioma And Non-Squamous Non-Small Cell Lung Carcinoma 2Biorem Reports Third Quarter Results 2Biorem Reports Third Quarter Results 3
... of siRNAs targeting , key ... cells. To identify genes involved in a given cellular process, , ... distinct response profiles such as ... Inc., who pioneered the field of High Content , ...
... , Up to 50X more activity and 350% greater ... Removes trace quantities of , DNA ... RNase-free and recombinant in , ... lower in RNase activity than bovine pancreas , ...
... ... fastest, easiest, and most consistent method for PAGE purification of small , ... which was designed for the visualization of small nucleic acids, the flashPAGE ... of RNA , and DNA. , ...
Cached Biology Technology:Using Validated siRNAs in Functional Genomic Assays 2Using Validated siRNAs in Functional Genomic Assays 3TURBO DNase: Hyperactive, Salt Tolerant DNase 2TURBO DNase: Hyperactive, Salt Tolerant DNase 3TURBO DNase: Hyperactive, Salt Tolerant DNase 4TURBO DNase: Hyperactive, Salt Tolerant DNase 5Ultra-Fast Purification of Small Nucleic Acids 2Ultra-Fast Purification of Small Nucleic Acids 3Ultra-Fast Purification of Small Nucleic Acids 4Ultra-Fast Purification of Small Nucleic Acids 5
(Date:11/4/2014)... (Nov. 4, 2014) – A majority of Madagascar,s 101 ... could have serious consequences for the rainforests they call ... the positive impacts lemurs can have on rainforest tree ... disappearance could have on the region,s rich biodiversity. , ... fruits eaten by lemurs. Lemurs in turn disperse ...
(Date:11/3/2014)... DUBLIN , Nov. 3, 2014 Research ... report "Cell Therapy - Technologies, Markets and Companies" ... evaluates cell therapy technologies and methods, which have already started ... Hematopoietic stem cell transplantation is replacing the old fashioned bone ... described. Cell therapy is bound to become a part of ...
(Date:11/3/2014)... 3, 2014  NeuroSigma ® , Inc. (NeuroSigma), ... company focused on commercialization of its non-invasive ... treatment of neurological and neuropsychiatric disorders, announced today ... issued a Notice of Allowance for Mexican Patent ... by NeuroSigma and the Regents of the University ...
Breaking Biology News(10 mins):Gardeners of Madagascar rainforest at risk 2Gardeners of Madagascar rainforest at risk 3Global Cell Therapy - Technologies, Markets and Companies: 2014 Report 2Global Cell Therapy - Technologies, Markets and Companies: 2014 Report 3NeuroSigma Receives Notice of Allowance from the Mexican Institute of Industrial Property Covering Subcutaneous Trigeminal Nerve Stimulation (sTNS) 2NeuroSigma Receives Notice of Allowance from the Mexican Institute of Industrial Property Covering Subcutaneous Trigeminal Nerve Stimulation (sTNS) 3
... unusual symbiosis between tiny single-celled algae and highly specialized ... ecosystems, fertilizing the oceans by taking nitrogen from the ... organisms can use. Details of the symbiosis, ... , emerged from the investigation of a mysterious nitrogen-fixing ...
... development of new biocomposites based on the transformation ... for the construction sector. These innovative materials will ... BIocomposiTEs), a European Commission FP7 collaborative project co-participated ... (FI), EMPA (CH), EXERGY (UK), VERTECH (FR), ...
... pregnant makes a huge difference in the health of her ... ate before pregnancy might be important too. According to a ... Journal , what a group of female mice atebefore ... her offspring. These DNA alterations, called "epigenetic" changes, drastically affected ...
Cached Biology News:Unusual symbiosis discovered in marine microorganisms 2Unusual symbiosis discovered in marine microorganisms 3Unusual symbiosis discovered in marine microorganisms 4TECNALIA leads research to develop new biocomposites based on wheat straw and recycled paper 2A mother’s nutrition--before pregnancy--may alter the function of her children’s genes 2
... Ready-to-use liquid controls for monitoring Aldolase ... & abnormal) with targeted manufacturing values ... 20 ± 3 IU/L. 30-day ... at 2-8 C. Level 1: 3 ...
APOPTAG® Plastic Coverslips are designed to be custom fitted to the specific APOPTAG® kit application. Each coverslip has 2.5 x 1 dimensions....
Recombinant Mouse sTNF RII/TNFRSF1B...
Phospho-TAO2 (S181) Affinity Purified Polyclonal Ab Protein Family: Other Intracellular Kinases...
Biology Products: